Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034

The xerostomia therapeutics market size is expected to reach USD 2,993.61 million by 2034, according to a new study by Polaris Market Research. The report “Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The xerostomia therapeutics market focuses on products designed to manage dry mouth, a condition where the salivary glands do not produce enough saliva, leading to discomfort and potential oral health issues. The market includes salivary stimulants, substitutes, and oral care products aimed at relieving symptoms and improving oral health. The xerostomia therapeutics market growth is driven by factors such as an aging population, increasing awareness about xerostomia, and the rising prevalence of conditions such as Sjögren's syndrome and side effects from medications.

Xerostomia therapeutics market opportunities lie in the development of more effective and personalized treatments, with advancements in salivary stimulants and substitutes. Trends include the growing demand for over-the-counter solutions, innovations in oral healthcare products, and the expanding use of digital marketing strategies. Overall, the market demand is expected to grow steadily during the forecast period, fueled by the increasing number of affected individuals, the development of advanced treatment options, and the expanding awareness globally.

Xerostomia Therapeutics Market Report Highlights

The OTC segment, based on type, dominated the xerostomia therapeutics market share in 2024 due to the widespread availability and affordability of products, offering quick relief for dry mouth symptoms. However, the prescription segment is registering the fastest growth, driven by increasing cases of chronic conditions such as Sjögren's syndrome that require specialized treatments.

The salivary stimulants segment, by product, dominated the market share in 2024 as they are effective in stimulating saliva production, addressing the core issue of xerostomia.

North America dominated the xerostomia therapeutics market revenue share in 2024 due to the high prevalence of xerostomia and extensive healthcare access. Asia Pacific is the fastest growing due to increasing awareness of the condition, rising healthcare infrastructure, and a growing elderly population.

The market comprises several active companies offering various treatments for dry mouth. A few notable participants include Acacia Pharma; Church & Dwight Co., Inc.; Colgate-Palmolive Company; Forward Science; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Lupin Pharmaceuticals, Inc.; Mission Pharmacal Company; OraCoat; Parnell Pharmaceuticals, Inc.; Pendopharm; Pfizer Inc.; Recordati Industria Chimica e Farmaceutica S.p.A; Sun Pharmaceutical Industries Ltd.; and Synedgen, Inc.

Polaris Market Research has segmented the xerostomia therapeutics market report on the basis of type, product, and region:

By Type Outlook (Revenue – USD Million, 2020–2034)

OTC

Prescription

By Product Outlook (Revenue – USD Million, 2020–2034)

Salivary Stimulants

Salivary Substitutes

Dentifrices

By Regional Outlook (Revenue – USD Million, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America